Related references
Note: Only part of the references are listed.Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis
Hiro Goto et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice
Jane E. Dalton et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Combination therapy for visceral leishmaniasis
Johan van Griensven et al.
LANCET INFECTIOUS DISEASES (2010)
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Shyam Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
D. Schoenfeld et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony
Cesar Miranda-Verastegui et al.
PLOS NEGLECTED TROPICAL DISEASES (2009)
Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats
Snia Tugues et al.
HEPATOLOGY (2007)
Immune response to leishmania: paradox rather than paradigm
Parul Tripathi et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2007)
Visceral leishmaniasis: What are the needs for diagnosis, treatment and control?
Francois Chappuis et al.
NATURE REVIEWS MICROBIOLOGY (2007)
Resiquimod and other immune response modifiers as vaccine adjuvants
Mark A. Tomai et al.
EXPERT REVIEW OF VACCINES (2007)
Clinical and fundamental aspects of angiogenesis and anti-angiogenesis
I. Buysschaert et al.
ACTA CLINICA BELGICA (2007)
Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis
HW Murray et al.
INFECTION AND IMMUNITY (2005)
Interleukin 10 receptor blockade - pentavalent antimony treatment in experimental visceral leishmaniasis
HW Murray
ACTA TROPICA (2005)
The immunopathology of experimental visceral leishmaniasis
PM Kaye et al.
IMMUNOLOGICAL REVIEWS (2004)
Leishmaniasis: new approaches to disease control
CR Davies et al.
BRITISH MEDICAL JOURNAL (2003)
Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis
HW Murray et al.
INFECTION AND IMMUNITY (2003)
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy
HW Murray et al.
INFECTION AND IMMUNITY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
Clinical and experimental advances in treatment of visceral leishmaniasis
HW Murray
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis.
HW Murray et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis
HW Murray et al.
INFECTION AND IMMUNITY (2000)